Study of CH5132799 Administered Orally in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center, dose-escalation Phase I study to evaluate safety,
pharmacokinetics and activity of CH5132799 administered orally as a single agent in patients
with advanced solid tumors.